Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986553 in Refractory Autoimmune Diseases
NCT07873931Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2026
- Primary completion
- Oct 2032
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of BMS-986553 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc) and 3 more, sponsored by Bristol Myers Squibb. Primary endpoints: Treatment Emergent Adverse Events at 90 days, Serious Adverse Events at 90 days and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BMS-986553
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathies (IIM)systemic sclerosis (SSc)rheumatoid arthritis (RA)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07873931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873931.